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Abstract
Cholangiocarcinoma (CCA) is a heterogeneous group of malignancies that could develop at any level from the biliary 
tree. CCA is currently classified into intrahepatic (iCCA), perihilar and distal on the basis of its anatomical location. Of 
note, these three CCA subtypes have common features but also important inter-tumor and intra-tumor differences that 
can affect the pathogenesis and outcome. A unique feature of iCCA is that it recognizes as origin tissues, the hepatic 
parenchyma or large intrahepatic and extrahepatic bile ducts, which are furnished by two distinct stem cell niches, the 
canals of Hering and the peribiliary glands, respectively. The complexity of iCCA pathogenesis highlights the need of a 
multidisciplinary, translational and systemic approach to this malignancy. This review will focus on the advances of iCCA 
epidemiology, histo-morphology, risk factors, molecular pathogenesis, revealing the existence of multiple subsets of iCCA. 
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INTRODUCTION 
Cholangiocarcinoma (CCA) is a heterogeneous group of malignancies emerging at any level from the biliary 
tree[1-3] [Figure 1]. CCA is classified into intrahepatic (iCCA), perihilar (pCCA) and distal (dCCA) based on 
its anatomical location[1-3]. Of note, these three CCA subtypes have common features but also important 
inter-tumor and intra-tumor differences that can affect the pathogenesis and outcome[4-9]. The complexity 
of the pathogenesis and the pronounced heterogeneity affected in particularly iCCAs had impeded clinical 
goals in iCCA[10]. This review will focus on the advances of iCCA epidemiology, classifications and histo-
morphology, risk factors, molecular pathogenesis and clinical presentation revealing the existence of multiple 
subtypes of iCCA. 
THE BURDEN OF iCCA 
The epidemiologic trend of CCA shows a constant and dramatic increase in incidence and mortality 
worldwide[1-3], clearly depicting CCA relevance among others types of cancer. A progressive increase in 
intrahepatic CCA incidence was reported, while the incidences of both perihilar CCA and distal CCA seem 
to be stable[1-3]. The incidence of CCA in European countries ranges from 1 to more than 4 cases/100,000[1-3] 
[Figure 1]. However, the difficulties with classification coding for CCA, and with the various terminology that 
is used, determined an underestimation of CCA burden. In a recent report, the four ICD-10 (International 
Classification of Diseases) sub codes were agreed on for CCA and used[11]. This report showed that in England 
alone (not the whole of the UK), in 2013, 1965 new CCAs were diagnosed with an incidence rate of 3.65 per 
100,000 population, while, 2161 deaths and a mortality rate of 4.01 per 100,000 population were registered. 
The number of deaths per 100,000 population for the CCA in the period from 2010 to 2013 in England 
tragically surpassed the ones for the hepatocellular carcinoma (HCC), with 7743 vs. 6899 deaths in 2013 for 
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Figure 1. Worldwide incidence (cases/100,000) of cholangiocarcinoma (CCA). Data refer to the period 1971-2009. Green colour 
identifies areas with lower incidence (< 6/100,000 cases, rare cancer), while pink colour indicates countries where CCA is not a rare 
cancer (> 6/100,000 cases). Diagnoses have been classified according to the International Classification of Diseases (ICD-O-1, ICD-O-2, 
ICD-O-3, ICD-10, ICD-V9, ICD-V10, ICD-O). Where available, the more incident form [intrahepatic (IH) vs . extrahepatic (EH) CCA] and 
the temporal trend of incidence (↑increasing trend; ↕stable trend; ↓decreasing trend) have been reported. This figure was modified from 
Banales et al .[3] with permission
CCA and HCC respectively[11]. The trend in iCCA incidence is paralleled also by the fact that mortality for 
primary liver cancer has become more uniform across Europe over recent years with an evident decline of 
HCC mortality, but, in contrast, intrahepatic CCA mortality has substantially increased for the most part of 
Europe[12,13]. Over recent years intrahepatic CCA accounted for over a fourth of all liver cancer deaths in men 
and 50% in women[12]. Liver cancer mortality rates are expected to rise by 58% in the UK between 2014 and 
2035, i.e., to 16 deaths per 100,000 people by 2035[14]. Considering epidemiology trend in primary liver cancer, 
half of deaths for primary liver cancer will be determined by intrahepatic CCA[12-14]. Furthermore, when the 
mortality rates for all malignancies are considered, the untargeted problem of CCA emerged clearly. Indeed, 
while a reduction of the mortality rate from 19 malignancies (comprising breast, lung, colon, etc.) was shown 
from 1990 to 2009 (US data), the mortality rate for malignancies of liver and bile ducts increased by more 
than 40% and 60% in females and males, respectively[15]. Finally, it is noteworthy to mention that CCA is the 
most frequent cause of metastasis of unknown origin, and thus further highlights how we still do not know 
the real burden of CCA[16].
NEW INSIGHTS INTO iCCA CLASSIFICATIONS 
A huge number of different classifications have been proposed for CCA[1-10,17]. The most updated one, but 
still discussed, identify on the basis of the anatomical localization the iCCA, the pCCA and the dCCA[1-3]. 
However, being a topographic classification it suffers several pitfalls, and, of course, it does not reflect 
different biological features. Firstly, it should be noted that, the diagnosis of CCA frequently occurs at an 
advanced stage, where, the differentiation between the intra-hepatic or extra-hepatic location results is very 
difficult, and sometimes impossible[1-3]. Since, small bile ducts and ductules are also present in the perihilar 
liver parenchyma, then, pCCA as iCCA, may originate either from these smaller ducts and this cannot be 
discriminated based on gross morphology. Similarly, the iCCA may originate from larger or smaller portion 
of intrahepatic biliary tree. Third, recent studies demonstrated how, from a pathological and molecular 
point of view, differences between pCCA and the iCCA originated from larger bile ducts ceased to exist and, 
therefore, the distinction between these two forms of CCA is losing relevance[4,9]. Taking into consideration 
the macroscopic pattern of growth, iCCA has been classified in mass-forming (MF), periductal infiltrating 
(PI), and intraductal growing (IG)[2,3]. As far as pCCA and dCCA are concerned, either a PI or IG pattern has 
been recognized. For pCCA a nodular + PI growth pattern predominates (> 80%)[2,5,17,18]. 
On the histological level, while, the vast majority of pCCA and dCCA are mucinous adenocarcinomas, 
iCCAs are highly heterogeneous tumors and several classifications have been proposed[4,5,9,19]. The small 
bile duct type (mixed) iCCAs display an almost exclusively MF growth pattern[4,5,9,19], and are frequently 
associated with chronic liver diseases (viral hepatitis or cirrhosis)[4,5,9,19,20]. Notably, this subtype shares clinic-
pathological similarities with cytokeratin (CK) 19-positive hepatocarcinoma (HCC)[4,21]. On the other hand, 
large bile duct type (mucinous) iCCAs may grossly appear as MF, PI or IG types; they are more frequently 
associated with PSC and can be preceded by pre-neoplastic lesions such as biliary intraepithelial neoplasm 
(BiIN) or intraductal papillary neoplasm (IPNB)[4,5,9,19]. Interestingly, the large bile duct type (mucinous) 
iCCAs share phenotypic traits with pCCA and pancreatic cancers[4]. 
In our opinion, this histological subtyping should be taken into serious consideration because it underlines 
different risk factors, molecular profile, and clinical management[3,4,9,14,22-28].
MULTIPLE RISK FACTORS REVEAL iCCA SUBTYPE-SPECIFIC PATHOGENESIS
Although CCA is a rare cancer (incidence < 6/100,000) in most countries, its incidence may reach an extremely 
high in some populations of Chile, Bolivia, South Korea and North Thailand[29] [Figure 1]. The different 
prevalence of risk factor in geographic areas may explain the variation in incidence rates of CCA. For example, 
in Thailand regions, the very high incidence of CCA is closely related to the incidence of liver flukes[30-32]. 
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In order to review literature on risk factors associated with iCCA we have searched for case series of iCCA 
or case series with appropriate topographic classification of histologically verified iCCA. The risk factors 
of iCCA (diagnosed according the current recognized criteria, i.e. European RARECARE[33]) could be 
classified on the basis of the tissue or the cell which is primarily targeted by diseases or conditions and 
therefore likely involved in the carcinogenic process as cell or tissue of origin. For instance, biliary diseases 
as cholangitis/PSC, secondary biliary cirrhosis, choledocholithiasis, hepatolithiasis, cholecystitis, and liver 
flukes are pathologic conditions primarily affecting large intra-hepatic bile ducts [Table 1][34-46], and are risk 
factors for both iCCA and p/dCCA. Parenchymal liver diseases include chronic viral and non-viral liver 
diseases, recognize the interlobular bile ducts, bile ductules and the canals of Hering as the primary targets. 
Accordingly, these conditions are specific risk factors for iCCA [Table 1]. 
Other risk factors, like several toxic and environmental factors; amongst them nitrosamine-contaminated 
food, asbestos, dioxins, vinychlorides, and thorotrast as was always the case in the past[47], which hit multiple 
cellular targets, are considered risk factors associated to all CCA subtypes. 
PSC, a disease affecting both intra-hepatic and extra-hepatic bile ducts, represents the strongest independent 
risk factor both for iCCA and for pCCA [Table 1]. Most of the studies evaluated the cumulative risk of CCA 
in PSC patients, but not the discrete risk of iCCA and/or pCCA to PSC[48-51]. The cumulative incidence of 
CCA in PSC patients ranges from 5% to 10%[52-55]. Clinical and pathological observations suggested that 
PSC is specifically associated with the development of bile duct (mucinous) type CCA[4,56]. Data on the role 
of inflammatory bowel diseases (IBD), associated with or preceding PSC, in affecting the risk of CCA are 
controversial. The coexistence and duration of IBD significantly increased the risk of CCA in PSC patients[51]. 
In IBD patients the RR estimated was 2.61 for iCCA vs. 1.47 for pCCA[57]. Crohn’s disease (CD) seemed to 
have a lower risk of CCA than ulcerative cholitis (UC)[57,58]. In contrast, in a study carried out in the USA, 
neither IBD nor its duration confers additional risk of CCA in PSC patients[59].
In a study, Welzel et al.[36] described that duodenal ulcer disease was significantly more common among pCCA 
and iCCA cases than controls. Many studies have demonstrated associations between CCA and H. pylori but 
the correlation remains controversial and a direct cause-and-effect relationship has not been established[60-66]. In 
particular, in East-Asia, where iCCA represents a large proportion of primitive liver cancers, a strong association 
exists between liver fluke infestation (Ophistorchis viverrini and Clonorchis sinensis) and the development of 
CCA [Table 1][67,68]. Several epidemiological studies estimated the relationship between type II diabetes and 
CCA [Table 1][36,69-71]. Notably, a possible explanation of this association is attributable to a recent demonstration 
that in a diabetes model and in human subjects affected by type II diabetes, PBGs underwent proliferation 
and expansion in relation to hyperglycemia[72]. It’s worthy to note that metformin reduced the risk of iCCA in 
diabetic patients by a significant margin up to 60%[73,74]. A recent meta-analysis confirmed that, in addition to 
type II diabetes, even obesity, alcohol use and smoking, have an association with iCCA[75]. 
It is becoming increasingly evident that metabolic conditions predispose to the development of primary liver 
cancers[3,44,76]. Nonalcoholic fatty liver disease/non alcoholic steato-hepatitis (NAFLD/NASH) resulted in 
independent predictors of iCCA (not of pCCA development), even if with a less strong association compared 
with other risk factors (viral hepatitis, cirrhosis) [Table 1][76]. Hemochromatosis resulted in an independent 
predictor of iCCA development, and it failed to predict pCCA [Table 1]. 
It has long been known that the presence of cirrhosis increases the risk of iCCA[36,37,40,44,75]. HBV- and HCV-
related liver diseases have been identified as definitive risk factors for CCA, with a stronger association for 
iCCA than pCCA[77,78]. A meta-analysis by Palmer and Patel[75] concerning 8 case control studies indicated 
that HCV was associated with an overall OR of 4.84 for iCCA. Where the prevalence of the HBV infection 
is higher, the association with iCCA and HBV is more significant (e.g. Asian countries)[79,80]. The range of the 
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OR in the HbsAg positive subjects goes from 2.3 to 9.7 [Table 1][81]. The presence of cirrhosis increases the risk 
of CCA [Table 1] even more by 2.5 fold (95% CI: 1.2-5.1; P = 0.02) in HBV, and 3.2 fold (95% CI: 1.231-8.148, 
P = 0.017) in HCV patients[41]. 
The burden of HCV in the last decades has been associated with the specific increase of the iCCA as well as 
the HCC[81]. Accordingly, clinical and pathological observations suggested that liver cirrhosis is specifically 
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Table 1. Summary of risk factors significantly associated to iCCA* as assessed by case control studies (odd ratios by multivariate 
analyses) 
Risk factors for iCCA Odds ratios for increased risk
Bile duct diseases and conditions
Cholecystitis[36] 8.5
Cholelithiasis[35,40] 10.23-13.5
Hepatolithiasis[37,39,40,43,77§] 50.0-4.8; 6.7§
Choledochal cysts[36,37,44,59] 10.7-43.03; 36.9
Choledocholithiasis[35,43] 4.17-33.35
Cholangitis/primary sclerosing cholangitis[36,44] 64.2-75.23
Biliary cirrhosis/PBC[36,44] 17.08-19.8
Cholecystectomy[36,39] 3.6-5.4
Digestive diseases
Inflammatory bowel diseases[36,58] 1.72-3.95 
Crohn’s disease[36,44] 1.68-2.4
Ulcerative colitis[36,44] 3.3-4.5
Duodenal ulcer[36] 3.4
Chronic pancreatitis[36] 5.9
Liver flukes
Clonorchis sinensis infection[38,42] 8.6-13.6
Endocrine disorders
Thyrotoxicosis[36] 1.5
Diabetes mellitus type II[37-39,43,75,86] 1.8-3.2
Metabolic conditions and general risks
Obesity[36,44] 1.7-1.71
Alcohol intake > 80 g/day[37,39,75] 1.52-5.21
Smoking[36,44] 1.3-2.1
Metabolic syndrome[44#] 1.32-1.83
Dyslipoproteinemia[44] 1.65
Hypertension[44] 1.63
Chronic liver diseases
Alcoholic liver disease[36,44] 3.1-5.69
Non specific cirrhosis[36,37,43,44,75] 18.24-28.79
Hemochromatosis[36] 2.6
Hepatic schitsomias[43] 11
Non alcoholic liver disease[36] 3
Unspecified viral hepatitis[44] 7.66
HCV infection[36-40,44,75,77§] 2.41-9.71; 9.7§
HCV infection plus cirrhosis[40]  8.53 
HBsAg positive[35,37-40,44,75,81°] 2.3-9.7; °2.35-4.3
HBsAg positive plus cirrhosis[35,40,41] 13-18
HBsAg negative/HBcAb positive[45,81°] 1.09-1.81°
Occupational exposure
Occupational exposure to asbestos[46] 4.81
*Histological verified cases; §iCCA cases comprise 2 cases of cHCC-CCA; #according the 2001 U.S. NCEP-ATP III definition; °Risk of 
CCA only in Asia. The table was prepared summarizing findings by case control studies investigating risk factors associated to iCCA 
as assessed by multivariate analyses. The case-control studies were selected from the papers individuated by the following terms, that 
were searched on PubMed: ("cholangiocarcinoma"[MeSH Terms] OR "cholangiocarcinoma"[All Fields]) AND ("risk factors"[MeSH 
Terms] OR ("risk"[All Fields] AND "factors"[All Fields]) OR "risk factors"[All Fields] OR ("risk"[All Fields] AND "factor"[All Fields]) OR 
"risk factor"[All Fields])) NOT ("review"[Publication Type] OR "review literature as topic"[MeSH Terms] OR "review"[All Fields]) AND 
English[lang]. The criteria selections of the works comprise moreover the case definition of CCA: histological verified cases series of 
iCCA with appropriate topographic classification (Klatskin tumours classified as pCCA and excluded from the iCCAs) 
associated with the development of small bile duct (mixed) type iCCA[4]. Ductular reaction is a marker 
strongly associated with the evolution of chronic liver disease in cirrhosis. The origin of the small bile duct 
type iCCA may be associated with the chronic proliferative activation of hepatic stem cells and mature 
hepatocytes senescence in chronic liver diseases[12,82]. Since cirrhosis, chronic hepatitis B and C, alcohol 
use, diabetes, and obesity are major risk factors for iCCA and HCC[75], a common pathogenesis of primary 
intrahepatic epithelial cancers has been suggested. The parallel worldwide reduction of mortality of HCC[12], 
which is highly correlated to viral infection and cirrhosis, and on the pandemic of metabolic disorders, 
suggests that metabolic risk factors are responsible for the rising clinical impact of iCCA. Interestingly 
we provided the pathologic basis of this epidemiology phenomenon since we demonstrated DM-induced 
proliferation of PBG cells[72].
MOLECULAR PROFILING AND THE IDENTIFICATION OF MULTIPLE iCCA SUBSETS
Although there exist enormous geographic and racial differences[3,83], generally, the prominent genetic 
alterations described in CCAs affect TP53 (DNA repair)[84-86], tyrosine kinase (KRAS, BRAF, SMAD4 and 
FGFR2)[8,84-88], protein tyrosine phosphatase (PTPN3)[89], deregulated WNT/CTNNB1[90] and Notch pathways, 
epigenetic (IDH1 and IDH2)[28,84,88,91,92], and chromatin-remodeling factors (MLLs, ARID1A, PBRM1 and 
BAP1)[84-86,88,91]. 
Chronic bile duct inflammation characterizes CCA risk factors[93-95]. Accordingly, it was demonstrated that the 
enzyme cyclooxygenase-2 (COX-2) is induced in CCA by both bile acids and oxysterols, the oxidation products 
of cholesterol that are increased in the bile during biliary inflammation[96,97]. Inflammatory cytokines may 
also upregulate the expression of inducible nitric oxide synthase (iNOS) in CCA. Notably, nitric oxide (NO) 
promotes DNA damage directly by inhibiting DNA repair mechanisms, thus promoting carcinogenesis[98,99]. 
Moreover, iNOS activation stimulates further the expression of COX-2[100]. Notably, the tumoral stroma seems 
to have a peculiar role in the amplification of the inflammation. While the tumor epithelium was defined 
by deregulation of the HER2 network and frequent over-expression of EGFR, the hepatocyte growth factor 
receptor (HGF/MET), pRPS6, and Ki67, the stroma was enriched in inflammatory cytokines[101].
In the chronic inflammation milieu of CCA emerging in hepatitis infection[88], recurrent genetic variants 
in the promoter of the human telomerase reverse transcriptase (TERT) were described[88]. This could be 
correlated with the pivotal role of this “longevity” enzyme in controlling stem cells. These cells are extremely 
challenged in these conditions because the senescence of the mature hepatocytes determines the secondary 
stem proliferative activation (e.g. ductular reaction)[12]. 
A dissection of the molecular heterogeneity of iCCA, conducted by the evaluation of gene expression profile 
(transcriptome), clinic-pathological traits, and patient outcomes in iCCA cases, has allowed the identification 
of 2 main biological classes of iCCA. The first inflammation class (38% of IH-CCA), characterized by activation 
of inflammatory signaling pathways, overexpression of cytokines, and STAT3 activation and; the second 
proliferation class (62% of IH-CCA), characterized by activation of oncogenic signaling pathways (i.e. RAS, 
MAP-kinase and HGF/MET), DNA amplifications at 11q13.2, deletions at 14q22.1, mutations in KRAS and 
BRAF, and gene expression signatures previously associated with poor outcomes for patients with HCC[7]. 
Molecular studies of human iCCA associated with liver flukes demonstrated over-expression of genes involved 
in xenobiotic metabolism (UGT2B11, UGT1A10, CHST4, SULT1C1). Whereas non-OV-associated iCCA showed 
enhanced expression of genes related to growth factor signaling (TGFBI, PGF, IGFBP1, IGFBP3)[32,102]. Possible 
mechanism associated with liver flukes carcinogenesis may emerge from the discovery of the draft genome of 
Clonorchis sinensis and transcriptomes of Clonorchis Sinensis and OV[103,104]. For instance, the evaluation of the 
putative signature of liver flukes associated CCA could help in screening and surveillance, with the perspective 
of an early diagnosis of infestation in subjects[102]. A putative role of liver fluke infestation in modulating 
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epigenetic has been suggested by the demonstration of promoter hypermethylation in a handful of target genes 
in a large cohort of iCCA (n = 102) associated with liver fluke infection[105]. 
CCA genetic susceptibility has been investigated in geographic areas where liver flukes are endemic. In these 
studies, specific haplotypes of COX2-coding gene (PTGS2) or IL8RB have been recently associated with a 
significant risk of CCA development[106]. 
As far as CCA emerging in PSC, different molecular signatures of the high oncogenic risk were described in 
PSC patients. KRAS mutations were found in 30% of bile fluid of PSC patients without evidence of CCA[107]. 
Since KRAS mutations are frequently observed in CCA, and since the mutational profiling can be performed 
in cell-free DNA of bile supernatant, this early mutagenic event into the bile duct carcinogenesis could be 
evaluated for screening purposes in PSC patients[108]. The inflammatory microenvironment has also been 
associated with an aberrant DNA methylation profile in CCA emergence in PSC patients, which provides 
survival signals for the tumor[109]. Even, an inherited increase in the risk of CCA development in PSC patients 
was demonstrated by studies concerning the natural killer cell receptor G2D receptor, where specific genetic 
variants have been described in PSC patients[110].
Heterogeneity of molecular profile of CCA provides a demonstration of how somatic mutagenesis and epigenome 
features are highly cell/lineage type-specific, and are largely driven by the pre-neoplastic tissue pathologic 
milieu (see inflammation). Indeed, at a molecular level, distinct patterns of genetic mutations, methylation, 
and expression profiling may differentiate iCCA from pCCA. iCCAs were significantly more frequently bcl-2+ 
and p16+, whereas pCCAs were more often p53+[111]. Miller et al.[112] revealed 545 genes with altered expression 
in p/dCCA and 2354 in iCCA. Mutations in IDH1 and IDH2 were found only in iCCA (n = 9), but in none 
of the examined p/dCCA (n = 22) and gallbladder cancer (n = 75)[113]. Recent papers confirmed liver fluke 
negative iCCAs are enriched for IDH mutants[14,28]. A cross-platform comparison of iCCA with pancreatic 
cancer and HCC further emphasizes the presence of distinct tumor subsets, suggesting similarities of the 
IDH mutants CCAs with the HCCs rather than pancreatic cancers[28]. Conversely, mutations in KRAS by 
tumor site demonstrated predominance in pCCAs (53.3% of hilar vs. 6.7% of peripheral type)[7]. As far as 
epigenetic abnormalities are concerned, methylation of RASSF1A was more common in pCCA than in iCCA, 
while the opposite was demonstrated for methylation of GSTP gene[114]. Other reported alterations uniquely 
associated with iCCA, comprised fibroblast growth factor receptor (FGFR) pathways and ephrin type-A 
receptor 2 mutations[115]. 
Finally, the histopathological distinction of cholangiolocellular differentiation of iCCA has been correlated with 
molecular features[115]. iCCA with cholangiolocellular differentiation resembling an inflammation-related subtype 
revealed less aggressive histopathological features compared to iCCA without cholangiolocellular differentiation 
resembling a proliferation subtype. Accordingly, the former showed more favorable clinical outcomes, including 
overall survival, than iCCA without cholangiolocellular differentiation[116]. The emerging therapeutic approaches 
based on the molecular targets in CCA have been recently reviewed by Rizvi and Gores[117].
VARIABLE CLINICAL PRESENTATIONS AND DIAGNOSTIC FEATURES
Clinical presentation of CCA is largely influenced by anatomic location and pattern of growth, which 
ultimately belong from the cells of the origin. Accordingly, emerging concepts into CCA origins 
demonstrated that it comprises at least two separate entities which a distinct histology, progression and 
risk factors. These sub-types have been recently classified in large bile duct (mucinous) type CCAs and the 
small bile ducts or mixed-CCAs. According to different observations, pCCAs are more likely associated 
with pre-neoplastic lesions emerging in surface epithelium[2,3] and PBGs[118]. On the other hand, iCCAs show 
inter-tumor heterogeneity leading to the classification into two main different histological subtypes[4,119], 
with likely different cells of origin[4]: the CCAs of the small bile ducts or mixed-CCAs and the large bile duct 
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(mucinous) type iCCAs[22,119]. The last iCCA subtype displays IHC, gene expression and clinic-pathological 
profile that can be superimposed on pCCA[4,120-122]. Small bile ducts or mixed-CCAs usually showed a peripheral 
localization and a mass forming growing pattern. Differently, the large bile duct (mucinous) type usually 
showed a peri-ductal infiltrating and/or mass forming growth pattern[4]. Importantly, these separate entities 
displayed different prognosis (being worst the one of the mucin-producing iCCAs) and different associated 
diseases[4,10,82,123]. Indeed, parenchymal liver diseases, including chronic viral and non-viral liver diseases and 
liver cirrhosis, characterize the clinical-pathologic background for mixed-iCCAs[4,10,82,123]. In contrast, chronic 
biliary diseases or pathologies and conditions affecting the intrahepatic medium-large and extrahepatic bile 
ducts characterize the clinical-pathologic background for mucin-producing iCCAs and pCCAs[4,10,82,123]. 
As far as the mixed type-mass-forming iCCA is concerned, the clinical presentation is similar to other 
intrahepatic liver malignancies, but different from that of pCCA[4,10,82,123]. iCCAs are usually asymptomatic 
in early stages (20%-25% of cases are incidental finding). Malaise, cachexia, abdominal pain, night sweats, 
fatigue and/or jaundice, associated or not with systemic manifestations, represent the clinical onset of 
symptomatic iCCA[4,10,82,123]. In contrast, a typically painless jaundice is the most frequent clinical onset in 
pCCA[4,10,82,123]. Regarding patients with PSC, CCA may present as the development of a rapid deterioration 
of clinical conditions or a dominant stricture during follow-up[3]. In general, the MF type represents the 
most frequent macroscopic presentation of iCCA (> 90%) appearing, at imaging, as a nodule[3,123]. In the 
context of cirrhotic liver, the first diagnostic challenge is the differential diagnosis of iCCA vs. HCC. In the 
cirrhotic liver it was demonstrated that by contrast, enhanced MRI iCCAs showed constantly a lack of HCC 
hallmarks; however, by CT, this occurs only in large nodules (> 3 cm)[124-126]. Although, the HCC diagnosis 
belong from the demonstration of the typical contrast agent uptake, the identification of HCC with stem 
cell features (CK19+-HCC), combined HCC-CCA, cholangiolocellular carcinoma and bile duct mixed type 
iCCA, by imaging procedures, still remains an unsolved challenge[3,4,10,123,127,128]. Biopsy is, therefore, necessary 
after excluding HCC in cirrhosis, or in the context of a nodule in non-cirrhotic liver[3,129]. From a histological 
point of view, differential diagnosis of iCCA vs. HCC or metastasis represents an unsolved problem[2,3,129,130], 
also due to the lack of validation of specific markers. 
Radiologically, iCCA may appear as a dominant stricture in the context of PSC or in patients without a 
documented specific hepato-biliary disease. This is a typical presentation of the pCCA. When a dominant 
stricture of the intrahepatic biliary tree is suspected, the MRI + MRCP represents the imaging procedure with 
the highest diagnostic accuracy for localizing and sizing the stricture[3]; the challenge being the definitive 
demonstration of malignancy[3]. In this respect, ERCP enables a number of procedures in order to obtain 
a microscopic confirmation, comprising, cytology, brushing, FISH-polisomy, biopsy, or further innovative 
techniques[3]. However, all these techniques show an unsatisfactory sensitivity[54,130-133], and even, the FISH-
polisomy in detecting CCA in PSC patients demonstrated a low sensitivity in a meta-analysis[133]. 
In substance, diagnosis of CCA still requires a combination of clinical, radiologic and non-specific histologic/
biochemical markers (see review by Banales et al.[3]).
As already mentioned, no specific serum, urine, biliary or histological biomarkers are currently available for 
the diagnosis of CCA and a proposal by our group which has been recently refreshed by new confirmation, 
identifies biliary IGF1 as specific markers of CCA. However, the very promising role of biliary IGF1 has 
been confirmed only in CCA without PSC. Recently, Arbelaiz et al.[134] evaluated the serum concentration 
of extracellular vesicles (EVs) and performed a careful analysis of the protein content in patients with CCA, 
PSC, and HCC. Proteomic signatures found in serum EV of CCA, PSC, and HCC patients show potential 
usefulness as diagnostic tools. As noted previously, the EV cargo in the two distinct EV populations (i.e., 
basolateral and apical) is evidently different as a large difference exists between the protein content of EVs 
released by normal cholangiocytes and cholangiocytes involved in chronic inflammation (i.e., PSC) or 
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neoplastic transformation (i.e., CCA)[135]. Further validation studies will be necessary to bring this important 
scientific advance into the clinical approach of CCA differential diagnosis.
NEW ADVANCES INTO CCA THERAPY
Surgery with complete resection, including liver transplantation in highly selected cases, is the only curative 
therapy for CCA. In patients with unresectable tumours, several types of loco regional therapy or chemotherapy 
(such as trans arterial chemoembolization, trans arterial radio embolization or radiofrequency ablation) can 
be considered. In substance, CCAs must be managed by dedicated centres with multidisciplinary expertise in 
which personalized diagnostic work-up and management can be performed, as clearly stated by a European 
Consensus (see review by Banales et al.[3]).
Recently two important advances have been reached in therapy of iCCA. On one hand, the first clinical 
trial of adjuvant therapy has been concluded[136]. In this clinical trial, 447 surgically resected patients 
were randomly assigned to capecitabine for 6 months or observation (> 80% of the patients were followed 
for at least 3 years). Interestingly, results showed a survival of 51 vs. 36 months in capecitabine arm vs. 
observation, and median time to cancer recurrence of 25 vs. 18 months, respectively. In 430 patients who 
received treatment per study protocol, capecitabine is associated with a 25% lower chance of death than 
observation[136]. On the other, the first report of a molecular target therapy in chemotherapy-refractory CCA 
appeared. BGJ398 was a first-in-class FGFR kinase inhibitor with manageable toxicities showing meaningful 
clinical activity against chemotherapy-refractory CCA containing FGFR2 fusions. This promising antitumor 
activity supports continued development of BGJ398 in this highly selected patient population[137]. Emerging 
therapeutic approaches based on the molecular targets are still in early phase of clinical study and have been 
recently reviewed by Rizvi and Gores[117].
PERSPECTIVES 
A unique feature of CCA is that it recognizes as origin tissues, the hepatic parenchyma or large bile ducts, 
which are furnished by two distinct stem cell niches, the canals of Hering and the peribiliary glands (PBGs), 
respectively[138]. 
Stem cells have been identified as cells of origin of different cancer types, comprising primary liver cancers, 
both in experimental studies and in humans[139-147]. Based on the grade of maturation of the cells of origin 
within the two lineages of the liver (hHpSC-derived and hBTSC-derived lineages), we have proposed that 
CCAs could be classified as:
• Primary liver parenchymal CCA: cholangiolo-carcinoma, small bile duct type (mixed) CCA. These tumors 
emerge within the liver parenchyma from canals of Hering, bile ductules and interlobular bile ducts and 
indeed originate from hHpSCs, immature NCAM+ cholangiocytes, or mature (NCAM-) interlobular 
cholangiocytes. A rigourous study, based on an integrative genomic analysis of HCC-CCAs, demonstrated 
that cholangiolo-carcinoma represents a distinct biliary-derived entity compared with the mixed/combined 
HCC-CCA, which, on the other side, comprised the stem-cell type, with an aggressive nature and poor 
outcome, and the classical type, with common cell lineage for both the HCC and the iCCA component[148].
• Primary biliary CCA: dCCA, pCCA, and large bile duct (mucinous) type iCCA. These tumors emerge from 
extra-hepatic biliary tree and larger intra-hepatic bile ducts and originate from PBGs or surface epithelium 
of corresponding bile ducts. 
Thus, facing the origin of iCCA, a physiopathology concept should be considered, instead of the cell of origin, 
the lineage of origin[10,12,13,138]. An iCCA classification based on the cell-lineages-of origin is more coherent 
with current knowledge on the epidemiology and risk factors and may have important clinical implications 
for the definition of specific therapeutic targets. Moreover, it highlights a lineage dependency of the chronic 
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liver diseases and related molecular carcinogenesis[12]. Being somatic mutagenesis and epigenome features 
highly cell/lineage type-specific[149], and largely driven by the pre-neoplastic tissue pathologic milieu (see 
inflammation), finally, the multiple lineages of origin plus the related diseases may explain the intertumoral 
heterogeneity observed at any level in iCCA, comprising molecular profiling, with clear implication into 
preventive strategies in patient with clinical or subclinical underlining hepatic or biliary diseases, therapy 
and in near future approaches of personalized medicine in iCCA patients.
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